These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 28633896

  • 1. Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
    Zhang L, Bu T, Bao X, Liang T, Ge Y, Xu Y, Zhu Q.
    Bioorg Med Chem Lett; 2017 Aug 01; 27(15):3395-3398. PubMed ID: 28633896
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y, Xin BT, Zhang Y, Wu J, Lu X, Zheng Y, Tang W, Zhou X.
    Eur J Med Chem; 2015 Jan 27; 90():170-83. PubMed ID: 25461318
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
    Fan YH, Li W, Liu DD, Bai MX, Song HR, Xu YN, Lee S, Zhou ZP, Wang J, Ding HW.
    Eur J Med Chem; 2017 Oct 20; 139():95-106. PubMed ID: 28800461
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y, Liu WJ, Yin L, Li H, Chen ZH, Zhu DX, Song XQ, Cheng ZZ, Song P, Wang Z, Li ZG.
    Bioorg Med Chem Lett; 2018 Mar 01; 28(5):974-978. PubMed ID: 29429832
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
    Wu YZ, Ying HZ, Xu L, Cheng G, Chen J, Hu YZ, Liu T, Dong XW.
    Arch Pharm (Weinheim); 2018 Jun 01; 351(6):e1700381. PubMed ID: 29708285
    [Abstract] [Full Text] [Related]

  • 7. Novel imidazo[2,1-b]thiazoles and imidazo[1,2-a]pyridines tethered with indolinone motif as VEGFR-2 inhibitors and apoptotic inducers: Design, synthesis and biological evaluations.
    Elkotamy MS, Elgohary MK, Al-Rashood ST, Almahli H, Eldehna WM, Abdel-Aziz HA.
    Bioorg Chem; 2024 Oct 01; 151():107644. PubMed ID: 39079394
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of 3-(4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridin-2-yl)-1H-quinolin-2-ones as VEGFR-2 kinase inhibitors.
    Han SY, Choi JW, Yang J, Chae CH, Lee J, Jung H, Lee K, Ha JD, Kim HR, Cho SY.
    Bioorg Med Chem Lett; 2012 Apr 15; 22(8):2837-42. PubMed ID: 22450128
    [Abstract] [Full Text] [Related]

  • 9. Design and synthesis of novel imidazo[4,5-b]pyridine based compounds as potent anticancer agents with CDK9 inhibitory activity.
    Ghanem NM, Farouk F, George RF, Abbas SES, El-Badry OM.
    Bioorg Chem; 2018 Oct 15; 80():565-576. PubMed ID: 30025343
    [Abstract] [Full Text] [Related]

  • 10. The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors.
    Stec MM, Andrews KL, Bo Y, Caenepeel S, Liao H, McCarter J, Mullady EL, San Miguel T, Subramanian R, Tamayo N, Whittington DA, Wang L, Wu T, Zalameda LP, Zhang N, Hughes PE, Norman MH.
    Bioorg Med Chem Lett; 2015 Oct 01; 25(19):4136-42. PubMed ID: 26298499
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.
    Baladi T, Aziz J, Dufour F, Abet V, Stoven V, Radvanyi F, Poyer F, Wu TD, Guerquin-Kern JL, Bernard-Pierrot I, Garrido SM, Piguel S.
    Bioorg Med Chem; 2018 Nov 01; 26(20):5510-5530. PubMed ID: 30309671
    [Abstract] [Full Text] [Related]

  • 12. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
    Garamvölgyi R, Dobos J, Sipos A, Boros S, Illyés E, Baska F, Kékesi L, Szabadkai I, Szántai-Kis C, Kéri G, Őrfi L.
    Eur J Med Chem; 2016 Jan 27; 108():623-643. PubMed ID: 26724730
    [Abstract] [Full Text] [Related]

  • 13. Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-d]Pyrimidine Series as Novel PI3K/mTOR Inhibitors.
    Buron F, Rodrigues N, Saurat T, Hiebel MA, Bourg S, Bonnet P, Nehmé R, Morin P, Percina N, Corret J, Vallée B, le Guevel R, Jourdan ML, Bénédetti H, Routier S.
    Molecules; 2021 Sep 02; 26(17):. PubMed ID: 34500781
    [Abstract] [Full Text] [Related]

  • 14. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
    Terao Y, Suzuki H, Yoshikawa M, Yashiro H, Takekawa S, Fujitani Y, Okada K, Inoue Y, Yamamoto Y, Nakagawa H, Yao S, Kawamoto T, Uchikawa O.
    Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7326-9. PubMed ID: 23147077
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and structure--activity relationship (SAR) studies of imidazo[4,5-b]pyridine derived purine isosteres and their potential as cytotoxic agents.
    Sajith AM, Abdul Khader KK, Joshi N, Reddy MN, Syed Ali Padusha M, Nagaswarupa HP, Nibin Joy M, Bodke YD, Karuvalam RP, Banerjee R, Muralidharan A, Rajendra P.
    Eur J Med Chem; 2015 Jan 07; 89():21-31. PubMed ID: 25462222
    [Abstract] [Full Text] [Related]

  • 16. The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor.
    Park JK, Kim S, Han YJ, Kim SH, Kang NS, Lee H, Park S.
    Bioorg Med Chem Lett; 2016 Jun 01; 26(11):2580-3. PubMed ID: 27117431
    [Abstract] [Full Text] [Related]

  • 17. Novel amino substituted tetracyclic imidazo[4,5-b]pyridine derivatives: Design, synthesis, antiproliferative activity and DNA/RNA binding study.
    Lončar B, Perin N, Mioč M, Boček I, Grgić L, Kralj M, Tomić S, Stojković MR, Hranjec M.
    Eur J Med Chem; 2021 May 05; 217():113342. PubMed ID: 33751978
    [Abstract] [Full Text] [Related]

  • 18. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y, Zhang T, Long L, Li Z, Wan S, Wang G, Yu Y, Hou J, Wu X, Zhang J.
    Eur J Med Chem; 2018 Jan 01; 143():182-199. PubMed ID: 29174814
    [Abstract] [Full Text] [Related]

  • 19. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.
    Xi JB, Fang YF, Frett B, Zhu ML, Zhu T, Kong YN, Guan FJ, Zhao Y, Zhang XW, Li HY, Ma ML, Hu W.
    Eur J Med Chem; 2017 Jan 27; 126():1083-1106. PubMed ID: 28039836
    [Abstract] [Full Text] [Related]

  • 20. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors.
    Qiu H, Ali Z, Bender A, Caldwell R, Chen YY, Fang Z, Gardberg A, Glaser N, Goettsche A, Goutopoulos A, Grenningloh R, Hanschke B, Head J, Johnson T, Jones C, Jones R, Kulkarni S, Maurer C, Morandi F, Neagu C, Poetzsch S, Potnick J, Schmidt R, Roe K, Viacava Follis A, Wing C, Zhu X, Sherer B.
    Bioorg Med Chem; 2021 Jun 15; 40():116163. PubMed ID: 33932711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.